GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal
Exelixis Inc EXEL
$49.90
▲ +2.53%
(+$1.23)
Open
$49.00
Prev Close
$48.67
Day Range
$48.88 – $50.20
52W Range
$33.76 – $51.63
Market Cap
$12.54B
P/E (TTM)
14.96
Beta
0.41
EPS (TTM)
$3.02
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2000-04-11 |
| Shares Out. | 251,360,000 |
| Website | exelixis.com/ ↗ |
| Phone | 13026587581 |
Exelixis Inc is a publicly traded company under the ticker symbol EXEL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
26 analysts (2026-05-01)
📰 Latest News for EXEL
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Exelixis Enters Clinical Development Collaboration With Merck For Its KEYTRUDA QLEX Injection In Combination With Zanzalintinib In The STELLAR-316 Phase 3 Trial
Prediction: This Stock Could Double By 2031
EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Case for Value Investors